The coverage wall just cracked.
Starting July 1, 2026, Medicare will do something it has never done in its 61-year history. It will pay for GLP-1 medications prescribed specifically for weight management - not for diabetes, not for cardiovascular risk reduction as a secondary diagnosis, but for obesity itself.
For two decades, federal law explicitly banned Medicare Part D from covering drugs used solely for weight loss. That was not an accident. It was a deliberate policy choice, written into statute and defended through every budget cycle since 2003. On July 1, that choice ends.
The Medicare GLP-1 Bridge Program gives eligible seniors access to Wegovy, Zepbound, and Foundayo at a $50 monthly copay. Medicare negotiated the price down from $1,000 to $1,350 per month to a $245 net per-month supply. The federal government absorbs the difference.
It is a bigger deal than the coverage it provides. It is a signal that Washington now officially treats obesity as a disease worth treating - and th…
